Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis

Issues to consider

Joel P. Thompson, Amir Abdolahi, Katia Noyes

Research output: Contribution to journalReview article

Abstract

Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, 'real-world' treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.

Original languageEnglish (US)
Pages (from-to)455-469
Number of pages15
JournalPharmacoEconomics
Volume31
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Cost of Illness
Multiple Sclerosis
Cost-Benefit Analysis
Uncertainty
Therapeutics
Disclosure
North America
Administrative Personnel
Health Care Costs
Population
Randomized Controlled Trials
Delivery of Health Care

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis : Issues to consider. / Thompson, Joel P.; Abdolahi, Amir; Noyes, Katia.

In: PharmacoEconomics, Vol. 31, No. 6, 06.2013, p. 455-469.

Research output: Contribution to journalReview article

Thompson, Joel P. ; Abdolahi, Amir ; Noyes, Katia. / Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis : Issues to consider. In: PharmacoEconomics. 2013 ; Vol. 31, No. 6. pp. 455-469.
@article{d86f4e4883464a14923be721af175ff7,
title = "Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: Issues to consider",
abstract = "Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, 'real-world' treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.",
author = "Thompson, {Joel P.} and Amir Abdolahi and Katia Noyes",
year = "2013",
month = "6",
doi = "10.1007/s40273-013-0063-4",
language = "English (US)",
volume = "31",
pages = "455--469",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis

T2 - Issues to consider

AU - Thompson, Joel P.

AU - Abdolahi, Amir

AU - Noyes, Katia

PY - 2013/6

Y1 - 2013/6

N2 - Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, 'real-world' treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.

AB - Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, 'real-world' treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.

UR - http://www.scopus.com/inward/record.url?scp=84878886342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878886342&partnerID=8YFLogxK

U2 - 10.1007/s40273-013-0063-4

DO - 10.1007/s40273-013-0063-4

M3 - Review article

VL - 31

SP - 455

EP - 469

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 6

ER -